High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response

M. A. Ferro; D. Gillatt; M. O. Symes; P. J B Smith

doi:10.1016/0090-4295(89)90248-3

High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response

M. A. Ferro^*, D. Gillatt, M. O. Symes, P. J B Smith

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

53 Citations (Scopus)

Abstract

High-dose intravenous estrogen therapy was shown to be effective in relieving bone pain due to metastatic disease in 22 of 29 (75.9 %) men with advanced hormone-resistant prostate cancer. This clinical response was accompanied by significant falls in serum prostate-specific antigen (PSA) levels in 13 (44.8%) patients. It is suggested that this clinical benefit is due to a direct inhibitory effect of estrogen on prostate cancer cells.

Original language	English
Pages (from-to)	134-138
Number of pages	5
Journal	Urology
Volume	34
Issue number	3
DOIs	https://doi.org/10.1016/0090-4295(89)90248-3
Publication status	Published - 1989
Externally published	Yes

Access to Document

10.1016/0090-4295(89)90248-3

Cite this

@article{c37c086a306047a4b3c54822183bc894,

title = "High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response",

abstract = "High-dose intravenous estrogen therapy was shown to be effective in relieving bone pain due to metastatic disease in 22 of 29 (75.9 %) men with advanced hormone-resistant prostate cancer. This clinical response was accompanied by significant falls in serum prostate-specific antigen (PSA) levels in 13 (44.8%) patients. It is suggested that this clinical benefit is due to a direct inhibitory effect of estrogen on prostate cancer cells.",

author = "Ferro, {M. A.} and D. Gillatt and Symes, {M. O.} and Smith, {P. J B}",

year = "1989",

doi = "10.1016/0090-4295(89)90248-3",

language = "English",

volume = "34",

pages = "134--138",

journal = "Urology",

issn = "0090-4295",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response

AU - Ferro, M. A.

AU - Gillatt, D.

AU - Symes, M. O.

AU - Smith, P. J B

PY - 1989

Y1 - 1989

N2 - High-dose intravenous estrogen therapy was shown to be effective in relieving bone pain due to metastatic disease in 22 of 29 (75.9 %) men with advanced hormone-resistant prostate cancer. This clinical response was accompanied by significant falls in serum prostate-specific antigen (PSA) levels in 13 (44.8%) patients. It is suggested that this clinical benefit is due to a direct inhibitory effect of estrogen on prostate cancer cells.

AB - High-dose intravenous estrogen therapy was shown to be effective in relieving bone pain due to metastatic disease in 22 of 29 (75.9 %) men with advanced hormone-resistant prostate cancer. This clinical response was accompanied by significant falls in serum prostate-specific antigen (PSA) levels in 13 (44.8%) patients. It is suggested that this clinical benefit is due to a direct inhibitory effect of estrogen on prostate cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=0024428990&partnerID=8YFLogxK

U2 - 10.1016/0090-4295(89)90248-3

DO - 10.1016/0090-4295(89)90248-3

M3 - Article

C2 - 2476882

AN - SCOPUS:0024428990

SN - 0090-4295

VL - 34

SP - 134

EP - 138

JO - Urology

JF - Urology

IS - 3

ER -

High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response

Abstract

Access to Document

Other files and links

Fingerprint

Cite this